Amarin Corporation plc (NASDAQ:AMRN)

Home >> Stock >> Amarin Corporation plc >> Reports

Amarin Corporation plc is a commercial-stage pharmaceutical company focused on developing therapies, especially based on omega-3 fatty acid for treating cardiovascular diseases. The company's sole marketed drug, Vascepa (icosapent ethyl) is approved in the United States as an adjunct to diet for treating severe hypertriglyceridemia or elevated triglyceride levels. The FDA approved Vascepa to reduce cardiovascular risk in patients with persistent elevated triglycerides on statin therapy for LDL-C. The drug received approval for both indications in Europe under the tradename of Vazkepa. It has initiated various promotional activities and direct-to-consumer programs as well as expanded its salesforce to support promotion of Vascepa's expanded label. A generic version of Vascepa has been launched for elevated TG levels....

+See More

Blog+More

U.S. tech titans increasingly hire PhD economists to help solve business problems.

Monica McNeil

2019-03-19 12:35:00 Tuesday ET

U.S. tech titans increasingly hire PhD economists to help solve business problems.

U.S. tech titans increasingly hire PhD economists to help solve business problems. These key tech titans include Facebook, Amazon, Microsoft, Google, Apple,

+See More

Blue-ocean strategists shift focus from current competitors to alternative non-customers with new market space.

Apple Boston

2020-05-21 11:30:00 Thursday ET

Blue-ocean strategists shift focus from current competitors to alternative non-customers with new market space.

Most blue-ocean strategists shift fundamental focus from current competitors to alternative non-customers with new market space. W. Chan Kim and Renee Ma

+See More

President Trump seeks to honor his campaign promise of lower U.S. medical costs by forcing higher big-pharma prices in foreign countries.

Charlene Vos

2018-05-07 07:32:00 Monday ET

President Trump seeks to honor his campaign promise of lower U.S. medical costs by forcing higher big-pharma prices in foreign countries.

President Trump seeks to honor his campaign promise of lower U.S. medical costs by forcing higher big-pharma prices in foreign countries such as Canada, Bri

+See More

The U.S. federal government debt has risen from less than 40% of total GDP about a decade ago to 78% as of May 2018.

John Fourier

2018-06-01 07:30:00 Friday ET

The U.S. federal government debt has risen from less than 40% of total GDP about a decade ago to 78% as of May 2018.

The U.S. federal government debt has risen from less than 40% of total GDP about a decade ago to 78% as of May 2018. The Congressional Budget Office predict

+See More

President Trump picks David Malpass to run the World Bank to curb international multilateralism.

Rose Prince

2019-02-07 07:25:00 Thursday ET

President Trump picks David Malpass to run the World Bank to curb international multilateralism.

President Trump picks David Malpass to run the World Bank to curb international multilateralism. The Trump administration seems to prefer bilateral negotiat

+See More

Fed's new chairman Jerome Powell testifies before Congress for the first time.

Rose Prince

2018-02-27 09:35:00 Tuesday ET

Fed's new chairman Jerome Powell testifies before Congress for the first time.

Fed's new chairman Jerome Powell testifies before Congress for the first time. He vows to prevent price instability for U.S. consumers, firms, and finan

+See More